The Galleri Test and Liquid Biopsies: Multi-Cancer Blood Tests, Honestly Assessed

A single tube of blood, drawn in five minutes, promising to check for dozens of cancers at once. If you are over 50, someone in your life has probably mentioned it—maybe a golf partner who paid out of pocket, maybe a podcast ad delivered in a soothing voice between segments.

The idea is genuinely seductive. Most cancers that kill people have no recommended screening test at all. No routine check exists for pancreatic, ovarian, or liver cancer, which tend to announce themselves late, when options have narrowed. A blood test that catches those quietly, years earlier, would change medicine.

So the question is not whether the concept is exciting. It is. The question is what the numbers actually show right now—and the numbers tell a far more complicated story than the marketing does. Here is that story, told straight.

What is the Galleri test, exactly?

Galleri is the best-known example of a category researchers call multi-cancer early detection, or MCED, tests. It requires a prescription, a standard blood draw, and about two weeks of waiting. The report that comes back says one of two things: no cancer signal detected, or cancer signal detected—along with a prediction of where in the body that signal most likely originated.

Two points deserve emphasis before anything else. First, this is a screening test, not a diagnostic one. A positive result does not mean you have cancer; it means you need imaging, scopes, or biopsies to find out. A negative result does not mean you are cancer-free; it means the test found no signal on that day, within the limits of its sensitivity.

Second, Galleri has not been approved by the Food and Drug Administration. It is offered as what regulators call a laboratory-developed test, performed in a single certified lab. That is a legal pathway, not a loophole, but it means the test reached the market without the kind of pre-approval review that, say, a new mammography technology would face. The National Cancer Institute notes that no MCED test has yet been shown in a completed randomized trial to reduce cancer deaths—the gold standard every established screening program has had to meet. That evidence is being gathered now. It does not exist yet.

How does a liquid biopsy actually work?

Every cell in your body sheds fragments of DNA into the bloodstream when it dies—skin cells, liver cells, blood cells, all of them. Scientists call this cell-free DNA. Tumors shed it too, and here is the useful part: cancer DNA carries distinctive chemical tags.

Those tags are methylation marks, tiny molecular flags that tell genes when to switch on or off. Cancer scrambles this pattern in characteristic ways, almost like a fingerprint smudged in a recognizable direction. Galleri sequences the cell-free DNA in a blood sample, reads more than 100,000 methylation regions, and runs the pattern through a machine-learning classifier trained on tens of thousands of samples from people with and without cancer.

The same methylation fingerprint does something else clever: because different tissues carry different baseline patterns, the test can predict the likely organ of origin—the report might point toward the pancreas or the lung, for instance. In validation studies, that prediction was correct roughly 88 to 89 percent of the time when cancer was actually present, which gives doctors a starting point for the diagnostic workup rather than a full-body scavenger hunt.

One physical reality shapes everything downstream: small, early tumors shed very little DNA. A stage I cancer may release so few fragments that they are simply undetectable in a single tube of blood. This is not a flaw engineers can easily fix. It is biology, and it explains most of the accuracy numbers you are about to see.

Which cancers does the Galleri blood test detect?

The manufacturer’s claim is that the test can detect a signal shared by more than 50 cancer types. That figure comes from the large case-control studies used to build and validate the classifier, and it includes both common cancers—lung, colorectal, breast, prostate—and rare ones such as cancers of the bile duct, small intestine, and certain soft tissues.

The more meaningful way to frame it: many of those 50-plus types currently have no recommended screening test at all. Pancreatic, ovarian, esophageal, stomach, and liver cancers together cause a large share of cancer deaths precisely because they are so often found late. If a blood test reliably caught them early, the public health impact would be substantial.

But detection is not uniform across that list. The test performs noticeably better with cancers that shed abundant DNA into blood—pancreatic, liver, ovarian, esophageal, and head-and-neck cancers among them. It performs worse with others:

• Early breast cancer, particularly hormone-receptor-positive types, is frequently missed.
• Low-grade prostate cancer sheds little DNA and often goes undetected—arguably a feature, since many such cancers never need treatment.
• Kidney and thyroid cancers and brain tumors are also detected at lower rates.

So the honest answer to “which cancers does it detect?” is: potentially many, reliably none. Every cancer type on the list can be missed, especially at stage I, and the list itself says nothing about how often each one is caught.

How accurate is the Galleri test? The numbers by stage

Accuracy has two halves, and the test’s two halves look very different. Start with specificity—how well it avoids false alarms in people without cancer. Here Galleri is genuinely strong: about 99.5 percent in the key validation study. Only about 5 people per 1,000 without cancer will get a false-positive signal. For a test screening for dozens of diseases at once, that is impressive engineering.

Sensitivity—how well it catches cancer that is actually there—is where honesty gets uncomfortable. Across all cancers and stages in the validation study, the test detected roughly half. Broken down by stage, the gradient is steep:

Cancer stage	Approximate detection rate	What that stage means
Stage I	~17%	Small, localized—the most treatable window
Stage II	~40%	Larger or locally spread
Stage III	~77%	Regional spread, often to lymph nodes
Stage IV	~90%	Distant spread

Read that top row again. The entire promise of screening is catching cancer early, and at stage I the test misses roughly five of every six cancers. It is most sensitive exactly when cancer is most advanced—when a diagnosis was likely coming soon anyway. Whether finding stage III and IV disease a few months earlier actually changes outcomes is one of the central unanswered questions in this field, and no one should pretend it has been answered.

What a positive predictive value of about 40 percent really means

Specificity of 99.5 percent sounds nearly perfect, so this next number surprises people: in the PATHFINDER study, which followed about 6,600 adults aged 50 and older who took the test in real-world conditions, only about 38 percent of positive signals turned out to be cancer.

How can both be true? Arithmetic. Cancer is uncommon in any given year, even among older adults. Screen 1,000 people aged 50-plus, and perhaps 10 to 15 have a detectable cancer. The test will catch some fraction of those—call it 5 to 7 true positives. Meanwhile, that excellent 99.5 percent specificity still produces about 5 false positives among the 985-plus people without cancer. True and false positives end up nearly even, which is why a positive result is closer to a coin flip than a verdict.

A 38 to 43 percent positive predictive value is actually respectable by screening standards—it beats mammography’s, where fewer than 10 percent of callbacks turn out to be cancer. But there is a crucial difference in what follows. A suspicious mammogram leads to a focused workup of one organ. A positive Galleri signal, especially if the predicted origin is wrong or vague, can trigger a cascade: scans, scopes, sometimes biopsies of organs deep in the abdomen. The stakes of each false alarm are higher, and anyone considering the test should walk in knowing a positive result starts an investigation, not a conclusion.

Is the Galleri test worth it? An honest assessment

Here is the fairest answer current evidence supports: for most people, it is a costly bet on a plausible but unproven idea—and if taking that bet crowds out proven screening, it is a bad trade.

The case for: the test is safe (it is a blood draw), false alarms are uncommon in absolute terms, and it does find real cancers, including some—pancreatic, ovarian, liver—that no standard screening would have caught. In PATHFINDER, roughly half the cancers detected were types with no recommended screening test. For those individuals, the test may genuinely have mattered.

The case against is heavier at the moment. The test misses most stage I cancers, so it cannot deliver on “catch it early” for the majority of tumors. A negative result can breed false confidence. A positive result is wrong more often than it is right, with months of anxious workup for those on the wrong side. And the foundational question—does this test actually prevent cancer deaths?—remains open. Every established screening program earned its place by answering that question in randomized trials. This one has not yet, and the largest trial’s early results were unconvincing enough that England’s health service chose to wait rather than expand.

Worth it, then, depends on what $949 a year means to you, how you handle uncertainty, and whether you have already done the screenings that are proven to work. In that order.

What happens after a positive Galleri result?

The report arrives with a cancer signal detected and one or two predicted origins—say, the upper gastrointestinal tract. What follows is not standardized, which is itself a problem researchers are working on.

Typically a doctor starts with imaging aimed at the predicted site: a CT scan, an endoscopy, perhaps a PET scan if initial tests come back clean but the signal remains unexplained. If the predicted origin is wrong—it is wrong roughly one time in ten even when cancer exists—the search widens. Some people cycle through multiple scans, specialist referrals, and biopsies before reaching an answer.

The PATHFINDER study measured this limbo directly, and the numbers deserve attention. People whose positive signal turned out to be true cancer reached a diagnosis in a median of 57 days. People whose signal was a false alarm spent a median of 162 days—more than five months—before being cleared. That is five months of appointments, radiation exposure from imaging, out-of-pocket costs (the workup usually is billed to insurance, positive test or not), and the particular dread of being told a lab found a cancer signal somewhere in your body.

Most people in the study said they would screen again, and reported anxiety was lower than researchers feared. But five months of uncertainty is a real harm, and it belongs on the scale when you weigh this decision—not in the fine print.

The quieter risk: false reassurance from a negative result

False positives get the headlines. The subtler danger runs the other direction.

Picture someone who pays for the test annually, gets “no cancer signal detected” each time, and starts to feel comprehensively checked. The colonoscopy slips a year. The mammogram feels redundant. Why endure the prep and the squeeze when a space-age blood test just gave the all-clear?

The math shows why that logic fails. At stage I—the stage screening exists to find—the test misses roughly 83 percent of cancers. Early breast cancers are among its more frequent misses. A negative result is meaningful evidence against a large, advanced, DNA-shedding tumor. It says remarkably little about the small, curable one that a colonoscopy would have removed as a polyp before it became cancer at all.

Colonoscopy prevents cancer, not just detects it, by clearing precancerous polyps. Mammography and low-dose CT lung screening have each demonstrated mortality reductions in randomized trials of hundreds of thousands of people. Cervical screening has cut death rates from that cancer by more than half over decades. No blood test replicates any of that yet.

The manufacturer itself states the test is meant to complement, not replace, standard screening. Behavioral drift is human nature anyway. If there is one sentence to carry out of this article, it is this: a negative multi-cancer blood test changes none of your existing screening due dates. Not one.

Does insurance pay for a Galleri test?

Usually not, and the reasons are structural rather than stingy.

The list price runs about $949 per test, and the manufacturer suggests annual use, so this is a recurring cost, not a one-time splurge. Most private insurers decline coverage because the test lacks FDA approval and because the U.S. Preventive Services Task Force—whose A and B recommendations trigger mandatory no-cost coverage under federal law—has issued no recommendation for any multi-cancer detection test. No recommendation, no coverage mandate.

Medicare presents an odd wrinkle: under current law, Medicare generally cannot cover a screening test in this category without either FDA approval or new legislation. Bills to create a Medicare coverage pathway for MCED tests have been introduced in Congress repeatedly but had not become law as of this writing. Some employers have added the test as a wellness benefit, and certain government health programs have run limited pilots, so a minority of people do get it partly or fully paid.

For everyone else it is an out-of-pocket decision, which raises an equity issue worth naming plainly: at nearly $1,000 a year, early access tilts toward the affluent—who, statistically, already have better cancer outcomes. One practical note if you do pay: a positive result leads to diagnostic workups billed through ordinary insurance, with ordinary deductibles and copays, and a false positive can leave you with those bills and no cancer. Budget for the possibility, not just the test.

What did the huge NHS trial find?

The most important experiment in this field is happening in England. The NHS-Galleri trial enrolled about 140,000 adults aged 50 to 77 starting in 2021—the largest study of a multi-cancer blood test ever run, and crucially a randomized one: half the participants have their blood tested annually, half have blood drawn and stored but untested. Comparing the groups can answer the question that case-control studies cannot: does screening with this test actually shift cancers to earlier stages, and ultimately save lives?

In 2024, England’s health service reviewed interim results and made a telling decision. Rather than proceed to a planned larger rollout of roughly a million tests, it announced it would wait for the trial’s final results, expected around 2026, because the early data did not meet the pre-set bar for expansion. The detailed interim numbers were not published, so outside experts cannot dissect them—but health systems rarely delay programs whose early data dazzle.

That is not a verdict of failure. Screening trials need years for benefits to surface, and a sober “wait for the data” is exactly how evidence-based medicine is supposed to work—arguably more rigorous than the U.S. approach of selling the test while the question is still open. But it is a clear, public signal from the world’s most watched trial: as of now, the case is not made. Anyone weighing the test deserves to know that.

What is the most accurate cancer test?

People searching this phrase usually want a single answer, and medicine cannot honestly give one—because “accurate” splits into different jobs. But if the question is which tests have proven they save lives, the list is short and specific.

Colonoscopy sits near the top for a reason no blood test can match: it prevents cancer by removing precancerous polyps during the same procedure that finds them. Stool-based tests, done regularly, are also effective and validated. Low-dose CT lung screening cut lung cancer deaths by about 20 percent in a major randomized trial of longtime smokers. Mammography has demonstrated mortality reductions across decades of trials. Cervical screening with Pap and HPV testing is arguably the greatest screening success story in history, turning a leading cause of cancer death into a largely preventable disease.

Notice what these have in common: each targets one cancer, in a defined population, on a schedule refined by evidence, with proof of benefit measured in lives. Their per-test accuracy statistics are sometimes unglamorous—mammography’s positive predictive value is far lower than Galleri’s—yet they work, because accuracy on paper matters less than outcomes in people.

For diagnosis, once symptoms or a suspicious finding exist, tissue biopsy remains the definitive test; no blood draw or scan substitutes for a pathologist examining actual cells. So the most accurate cancer test is really several tests, each doing its narrow job well. Breadth is Galleri’s selling point. Depth of proof is everything else’s.

Can a blood test replace mammograms and colonoscopies?

No—and this is the one point on which the manufacturer, regulators, and independent researchers all agree without qualification. The test’s own labeling says it is intended to be used in addition to recommended screenings, not instead of them.

The logic bears repeating because the temptation is so understandable. Standard screenings are inconvenient by design: bowel prep, compression paddles, scheduling, discomfort. A blood draw feels like the future. But look at what each tool actually does for the specific cancers standard screening covers:

• Colonoscopy removes precancerous polyps on the spot—prevention, not just detection. A blood test can only flag cancer that already exists and is shedding DNA.
• Mammography detects many breast cancers at sizes and stages the blood test routinely misses; early breast cancer is one of Galleri’s documented weak spots.
• Low-dose CT finds early lung nodules in high-risk people with proven mortality benefit; the blood test’s stage I sensitivity cannot approach that.
• Cervical screening catches precancerous changes years before invasive cancer develops—territory a cancer-signal test never enters.

The sensible mental model: standard screenings are deep, proven coverage of four or five cancers. A multi-cancer blood test is shallow, unproven coverage of dozens more. Shallow-plus-deep might eventually beat deep alone—trials will tell. Shallow instead of deep is strictly worse, today and for the foreseeable future.

Who might reasonably consider a multi-cancer blood test?

Screening decisions are personal, but some situations make the calculus more favorable than others, and it is worth being concrete.

The strongest candidate looks something like this: over 50 (cancer risk, and thus the test’s usefulness, climbs with age), fully current on every recommended screening, able to absorb the cost without strain, with a family history that raises concern about cancers lacking standard screening—pancreatic cancer in a parent, for example—and temperamentally able to handle a possible false alarm and its months-long workup without spiraling. Elevated-risk groups such as longtime smokers were also where PATHFINDER-style studies found more cancers per test performed.

The weaker candidate: under 50, where low cancer rates mean positive results are even more likely to be false; anyone behind on colonoscopy, mammography, cervical, or lung screening, because catching up on those delivers proven benefit before speculative benefit; anyone for whom $949 a year is a genuine sacrifice; and anyone who suspects a negative result would tempt them to skip the screenings that actually work.

Two groups should specifically not use it as designed: people with active symptoms (that is diagnostic territory, covered below) and cancer survivors in surveillance, whose follow-up should follow their oncology team’s protocol, not a general screening product.

If you land in the reasonable-candidate column, the right next step is a conversation with your clinician about your specific risk profile—since a prescription is required anyway, that conversation is unavoidable, and it should be a real one.

When to see a doctor: symptoms outrank any screening test

Everything above concerns people who feel fine. The moment symptoms enter the picture, screening logic no longer applies—and no blood test result, positive or negative, should delay a medical evaluation.

See a doctor promptly, regardless of any recent screening result, if you notice:

• Unexplained weight loss—roughly 10 pounds or more without trying
• Blood where it should not be: in stool, urine, or coughed-up phlegm, or unusual vaginal bleeding, including any bleeding after menopause
• A lump or thickening anywhere, including breast, testicle, or lymph node areas
• A change in bowel habits, persistent bloating, or difficulty swallowing lasting more than a few weeks
• A cough or hoarseness that will not resolve after three to four weeks
• A sore or skin spot that does not heal, or a mole changing in size, shape, or color
• Night sweats that soak bedding, persistent unexplained fevers, or deep fatigue that rest does not touch
• New, persistent pain without an obvious cause, especially bone or abdominal pain

Most of these symptoms turn out to be something other than cancer. That is genuinely reassuring—and also beside the point, because the ones that are cancer are most treatable when investigated early. A recent “no cancer signal detected” report is the most dangerous possible reason to ignore a symptom, given how many early cancers the test misses. Symptoms get evaluated. Always. That rule predates liquid biopsies and will outlast every test on the market.

Frequently asked questions

Is the Galleri test worth it?

For most people, not yet—it is an unproven bet that only makes sense as an add-on. The test misses roughly five of six stage I cancers, positive signals are false more often than true, and no completed trial shows it saves lives. It becomes more defensible for someone over 50 who is fully current on proven screenings, can comfortably afford about $949 yearly, and understands a positive result means months of follow-up testing.

Which cancers does the Galleri blood test detect?

It screens for a DNA methylation signal shared by more than 50 cancer types, including pancreatic, ovarian, liver, and esophageal cancers that have no standard screening test. Detection is uneven, though: cancers that shed abundant DNA into blood are caught more often, while early breast cancer, low-grade prostate cancer, and kidney and thyroid cancers are frequently missed. Every type on the list can go undetected, especially at stage I.

Does insurance pay for a Galleri test?

Usually no. Most private insurers decline coverage because the test lacks FDA approval and no U.S. Preventive Services Task Force recommendation exists to mandate it. Medicare generally cannot cover it under current law, though legislation to change that has been proposed. Some employers offer it as a wellness benefit, and limited pilot programs have covered it, but most people pay the roughly $949 list price out of pocket.

What is the most accurate cancer test?

No single test wins; accuracy depends on the job. For diagnosis, tissue biopsy remains definitive. For screening, the proven performers are colonoscopy (which prevents colorectal cancer by removing polyps), mammography, low-dose CT for eligible smokers, and cervical Pap/HPV testing—each backed by trials showing fewer deaths. Galleri covers more cancer types than any of them but has not yet demonstrated that its breadth translates into lives saved.

Is the Galleri test FDA approved?

No. It is offered as a laboratory-developed test performed in a single certified laboratory, a legal pathway that does not require FDA pre-approval. The manufacturer has been pursuing full approval, but as of this writing no multi-cancer early detection test has received it. This regulatory status is a major reason insurers, including Medicare, generally decline to cover the test.

Can Galleri replace a colonoscopy or mammogram?

No, and even the manufacturer says so explicitly in its labeling. Colonoscopy prevents cancer by removing precancerous polyps—something no blood test can do—and mammography catches early breast cancers that Galleri routinely misses. The blood test is designed to add coverage for cancers that lack standard screening, not to substitute for screenings with decades of proof behind them. All existing screening schedules stay exactly the same.

What does a positive Galleri result mean?

It means further testing is needed—not that you have cancer. In the real-world PATHFINDER study, only about 38% of positive signals were confirmed as cancer. The report predicts the likely organ of origin, which guides imaging, scopes, or biopsies. True positives reached diagnosis in a median of 57 days; false positives took a median of 162 days to resolve, so patience and a systematic workup matter.

How much does the Galleri test cost?

The list price is about $949 per test, typically paid out of pocket since insurance rarely covers it. Because the manufacturer recommends annual testing, the realistic cost is closer to $950 every year. Follow-up testing after a positive result—scans, endoscopies, biopsies—is billed separately through regular insurance, with normal deductibles and copays, and those costs apply even when the signal turns out to be a false alarm.

How often should you take a multi-cancer blood test?

The manufacturer suggests annual testing for adults at elevated risk, such as those 50 and older, reasoning that a yearly draw improves the chance of catching a tumor once it sheds detectable DNA. No independent body has validated that interval, however, because no trial has yet established the test’s benefit at any frequency. The ongoing English randomized trial uses annual testing, so its final results should clarify whether that schedule delivers measurable value.

Can a blood test really detect cancer before symptoms appear?

Sometimes, yes—studies confirm these tests find real, asymptomatic cancers, including types with no standard screening. The unresolved question is whether finding them this way actually changes outcomes, since the test detects advanced cancers far more reliably than stage I disease. England’s 140,000-person randomized trial is designed to answer exactly that; its interim results in 2024 were not strong enough for health officials to expand the program, and final data are expected around 2026.

References

• MedlinePlus — Tumor Marker Tests
• World Health Organization — Cancer fact sheet

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.